Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761328 · ClinicalTrials.gov registry record · NA
Fear of Recurrence and Stopping Immunotherapy
A NA study of Cognitive Behavioral Therapy, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04761328: Recruiting NA study of Cognitive Behavioral Therapy, sponsored by University of Pittsburgh.
NCT04761328 is a NA study of Cognitive Behavioral Therapy that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 100 participants, below the 176-participant average among 8 other Cognitive Behavioral Therapy trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04761328, a NA study of Cognitive Behavioral Therapy, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.
Primary Outcome
Change by 50%
Conditions Studied
Interventions
- BEHAVIORAL cognitive behavioral therapy
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Centers - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT04761328 shows while recruiting
NCT04761328 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 8 other Cognitive Behavioral Therapy trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Cognitive Behavioral Therapy appearing as the primary indexed condition, and to 1 intervention - of which cognitive behavioral therapy is the first listed.
NCT04761328 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04761328 about?
NCT04761328 is a clinical study titled "Fear of Recurrence and Stopping Immunotherapy". The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.
What is the current status of trial NCT04761328?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2021-08-02. Estimated completion is 2028-12-31.
What conditions does trial NCT04761328 study?
This clinical trial studies the following conditions: Cognitive Behavioral Therapy.
What interventions are being tested in trial NCT04761328?
The interventions under investigation include: cognitive behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT04761328?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04761328 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Behavioral Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04761328's enrollment target sits among peer trials
100 6th of 8 higher than 3 of 8 other Cognitive Behavioral Therapy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Behavioral Therapy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
RECRUITING · NA
-
CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms
RECRUITING · NA
-
AI-Based Fidelity Feedback to Enhance CBT
RECRUITING · NA
-
Novel Mental Health Therapies to Improve Military Readiness
RECRUITING · NA
-
Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans
RECRUITING · NA
-
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI